- Home
- NMRA vs CCCC Comparison
NMRA vs CCCC Comparison
Compare NMRA & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- CCCC
- Stock Information
- Founded
- NMRA 2019
- CCCC 2015
- Country
- NMRA United States
- CCCC United States
- Employees
- NMRA N/A
- CCCC N/A
- Industry
- NMRA
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- NMRA
- CCCC Health Care
- Exchange
- NMRA Nasdaq
- CCCC Nasdaq
- Market Cap
- NMRA 287.6M
- CCCC 244.9M
- IPO Year
- NMRA 2023
- CCCC 2020
- Fundamental
- Price
- NMRA $1.80
- CCCC $3.01
- Analyst Decision
- NMRA Strong Buy
- CCCC Buy
- Analyst Count
- NMRA 6
- CCCC 5
- Target Price
- NMRA $20.67
- CCCC $11.60
- AVG Volume (30 Days)
- NMRA 2.0M
- CCCC 1.8M
- Earning Date
- NMRA 03-06-2025
- CCCC 03-04-2025
- Dividend Yield
- NMRA N/A
- CCCC N/A
- EPS Growth
- NMRA N/A
- CCCC N/A
- EPS
- NMRA N/A
- CCCC N/A
- Revenue
- NMRA N/A
- CCCC $33,668,000.00
- Revenue This Year
- NMRA N/A
- CCCC $75.59
- Revenue Next Year
- NMRA N/A
- CCCC N/A
- P/E Ratio
- NMRA N/A
- CCCC N/A
- Revenue Growth
- NMRA N/A
- CCCC 65.45
- 52 Week Low
- NMRA $1.60
- CCCC $2.79
- 52 Week High
- NMRA $21.00
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- NMRA 27.76
- CCCC 33.55
- Support Level
- NMRA $1.61
- CCCC $2.79
- Resistance Level
- NMRA $1.80
- CCCC $3.38
- Average True Range (ATR)
- NMRA 0.11
- CCCC 0.20
- MACD
- NMRA 0.23
- CCCC -0.03
- Stochastic Oscillator
- NMRA 51.28
- CCCC 23.66
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.